Morgan Stanley lowered the firm’s price target on Regenxbio (RGNX) to $16 from $17 and keeps an Overweight rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGNX:
- Regenxbio price target lowered to $14 from $25 at BofA
- Regenxbio price target lowered to $12 from $37 at Barclays
- Midday Fly By: Cisco reports Q3 beat, Chinese firms cleared to buy Nvidia chips
- Regenxbio reports Q1 EPS ($1.72) vs. 12c last year
- Regenxbio expects cash, equivalents to fund operations into early 2027